Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Case 1: Heavily Treatment–Experienced Patient—Part 2

In this on-demand webcast of a live roundtable, expert faculty consider the integrated approaches needed to address barriers to ART adherence and to select an effective new regimen for an older man with long-standing HIV infection, several comorbidities, and a complex treatment history with multiclass drug resistance. Then the expert panel discusses the best management strategies for a patient who is gaining excess weight on an INSTI- and TAF-containing first-line regimen.
Babafemi Taiwo, MBBS
Program Director
Rajesh T. Gandhi, MD
Daniel R. Kuritzkes, MD
Released: October 29, 2021

This program is divided into several short segments that you can step through using the Video Chapters menu.

Information on this Educational Activity

Program Director

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief,
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV and funds for research support from Janssen.

Faculty

Rajesh T. Gandhi, MD

Professor of Medicine
Department of Infectious Diseases
Harvard Medical School
Physician, Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Rajesh T. Gandhi, MD, has disclosed that he has received consulting fees from Merck.
Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received funds for research support rom Atea, Gilead Sciences, Merck, Novartis, and ViiV and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Rigel, and ViiV.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Julie Skowronski, NP
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Sarah Anderson, PharmD
Scientific Director
Sarah L. Anderson, PharmD, BCACP, BCPS, FASHP, FCCP, has no relevant conflicts of interest to report.

Target Audience

This program is intended for pathologists and other healthcare providers who treat and manage patients with lung cancer.

Goal

The goal of this activity is to improve participants’ knowledge of and competence in assessing biomarkers to guide the use of immune checkpoint inhibitors in the treatment of patients with lung cancer.

Program Medium

This program has been made available online.

Related Content

Dr Rodrigo Burgos discusses managing ART for people with HIV who are heavily treatment experienced, from Clinical Care Options (CCO)

person default Rodrigo Burgos, PharmD, MPH Released: February 6, 2023

Dr. José Arribas discusses the use of proviral DNA resistance testing when switching therapy in people with HIV, from Clinical Care Options (CCO)

José R. Arribas, MD Released: February 6, 2023

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

Slides on HIV ART management in complex clinical situations, including extensive previous treatment, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: January 11, 2023

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Merck Sharp & Dohme Corp.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings